Silvant Capital Management LLC Cuts Stake in Natera, Inc. (NASDAQ:NTRA)

Silvant Capital Management LLC trimmed its stake in Natera, Inc. (NASDAQ:NTRA) by 2.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 13,342 shares of the medical research company’s stock after selling 380 shares during the quarter. Silvant Capital Management LLC’s holdings in Natera were worth $1,694,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC grew its stake in shares of Natera by 1,073.1% during the 2nd quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock valued at $7,118,000 after buying an additional 60,127 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of Natera by 15.1% in the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock worth $6,810,000 after purchasing an additional 9,781 shares during the period. Natixis acquired a new position in shares of Natera in the 1st quarter valued at about $758,000. Baader Bank Aktiengesellschaft purchased a new stake in shares of Natera during the 2nd quarter worth about $478,000. Finally, Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in Natera during the 1st quarter worth approximately $33,956,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. TD Cowen lifted their price target on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, August 9th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Friday, October 25th. Piper Sandler reiterated an “overweight” rating and issued a $150.00 price target on shares of Natera in a report on Friday, September 13th. Stephens restated an “overweight” rating and set a $125.00 price objective on shares of Natera in a research note on Friday, August 9th. Finally, Robert W. Baird upped their target price on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $125.69.

Natera Stock Up 2.6 %

Shares of NASDAQ:NTRA opened at $124.16 on Friday. The firm has a market cap of $15.36 billion, a PE ratio of -50.68 and a beta of 1.53. The company has a fifty day simple moving average of $123.40 and a 200 day simple moving average of $112.23. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. Natera, Inc. has a 12-month low of $40.17 and a 12-month high of $133.54.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. The business had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company’s quarterly revenue was up 58.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.97) earnings per share. On average, equities research analysts anticipate that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Insider Transactions at Natera

In related news, insider Jonathan Sheena sold 2,700 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $113.82, for a total transaction of $307,314.00. Following the sale, the insider now directly owns 299,441 shares of the company’s stock, valued at approximately $34,082,374.62. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Steven Leonard Chapman sold 5,583 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $118.91, for a total transaction of $663,874.53. Following the completion of the transaction, the chief executive officer now directly owns 200,710 shares of the company’s stock, valued at approximately $23,866,426.10. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 2,700 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $113.82, for a total value of $307,314.00. Following the sale, the insider now owns 299,441 shares in the company, valued at $34,082,374.62. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,164 shares of company stock worth $6,157,291. 7.60% of the stock is currently owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.